Seer’s Proteograph™ Product Suite identifies undiscovered links between protein variants and lung cancer progression
March 29 2023 - 2:00PM
Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a
disruptive new platform for proteomics, today announced a new
scientific publication in PLOS One demonstrating the unmatched
utility of the Proteograph Product Suite to uncover novel insights
in human health and disease with deep, unbiased proteomics.
Scientists from Seer in collaboration with Luis Diaz, M.D. from
Memorial Sloan Kettering Cancer Center found previously unknown
associations between four protein isoforms and non-small cell lung
cancer (NSCLC) progression, constituting potential novel,
disease-relevant biomarkers, or therapeutic targets. Importantly,
the identified NSCLC-associated protein isoforms comprise
structural variants of proteins that arise from distinct but
related mRNAs produced from the same gene through the process of
alternative splicing. Different protein isoforms can have distinct
roles in biology, influencing disease predisposition and
progression. Notably, discovery and quantification of such protein
variants in a complex biological sample requires deep, unbiased
interrogation of the proteome at peptide-level resolution.
“These findings demonstrate that distinct protein isoforms may
differentially contribute to diverse biological mechanisms and to
the pathogenesis of cancers, potentially paving the road to
identify new diagnostic markers or new therapeutic targets,” said
Dr. Diaz, Head of the Division of Solid Tumor Oncology at Memorial
Sloan Kettering Cancer Center. “What is especially encouraging here
is that these protein isoforms were detected in plasma, a readily
accessible sample type, enabling cancer detection and monitoring
through liquid biopsy evaluation of patients.”
The researchers found that the short protein isoform of bone
morphogenetic protein 1 (BMP1) occurred more frequently in NSCLC
patients compared with healthy participants, and with even greater
abundance in patients with late-stage cancer, suggesting that this
isoform of BMP1 may play a role in NSCLC progression. BMP1 is
involved in collagen processing, and the short isoform of the
protein lacks the ability to release collagen, which could impact
the tumor microenvironment.
The study analyzed 188 plasma proteomes from NSCLC patients and
controls to identify disease-associated protein isoforms. In
addition to BMP1, the analysis revealed three other protein
isoforms with significant differential behavior in NSCLC when
compared to healthy controls: complement component 4a (C4a),
complement component 1r (C1r) and lactate dehydrogenase B
(LDHB).
“This study, which found disease-associated protein isoforms in
NSCLC, could only have been achieved using an unbiased
peptide-level approach that provides a deeper, more nuanced view of
the human proteome,” said Asim Siddiqui, Senior Vice President of
Research at Seer. “These findings demonstrate the power of unbiased
proteomics to discover novel biology, especially in the context of
cancer, that may otherwise be missed by genomics or targeted
proteomics.”
Further research is necessary to validate the utility of these
protein isoforms as novel biomarkers for NSCLC, or even new
therapeutic targets.
Seer’s Proteograph Product Suite enables proteomics studies with
an unprecedented combination of speed, scale, depth, and breadth of
data, allowing an unbiased interrogation of the proteome to allow
studies not previously possible. Seer’s proprietary engineered
nanoparticles deliver reproducible performance across samples,
labs, and experiments, providing peptide level information that is
key to identifying protein variants. The accompanying Proteograph
Analysis Suite offers cloud-scalable software for proteomic data
analysis, visualization, and generation of biological insights. The
Proteograph Product Suite makes it easy to add unbiased, deep,
rapid proteomics studies at scale to any lab.
About SeerSeer is a life sciences company
developing transformative products that open a new gateway to the
proteome. Seer’s Proteograph™ Product Suite is an integrated
solution that includes proprietary engineered nanoparticles,
consumables, automation instrumentation and software to perform
deep, unbiased proteomic analysis at scale in a matter of hours.
Seer designed the Proteograph workflow to be efficient and easy to
use, leveraging widely adopted laboratory instrumentation to
provide a decentralized solution that can be incorporated by nearly
any lab. Seer’s Proteograph Product Suite is for research use only
and is not intended for diagnostic procedures. For more
information, please visit www.seer.bio.
Forward-Looking StatementsThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended. Such
forward-looking statements are based on Seer’s beliefs and
assumptions and on information currently available to it on the
date of this press release. Forward-looking statements may involve
known and unknown risks, uncertainties and other factors that may
cause Seer’s actual results, performance, or achievements to be
materially different from those expressed or implied by the
forward-looking statements. These statements include but are not
limited to statements regarding access to proteins, discovery and
quantification of protein variants and biological insights,
identification and utility of protein isoforms as novel biomarkers
and therapeutic targets, deep unbiased interrogation of the
proteome at the peptide level, the role of BMP1 in NSCLC
pathogenesis and treatment resistance, the role of BMP1 in collagen
processing and the tumor microenvironment, the ability of the
Proteograph Product Suite to enable proteomics studies with an
unprecedented combination of speed, scale, depth, and breadth of
data. These and other risks are described more fully in Seer’s
filings with the Securities and Exchange Commission (“SEC”) and
other documents that Seer subsequently files with the SEC from time
to time. Except to the extent required by law, Seer undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Media Inquiries:Elizabeth Eatonpr@seer.bio
Investor Inquiries:Carrie
Mendivilinvestor@seer.bio
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jul 2023 to Jul 2024